New Mexico retailers report six-figure losses after the tracking-system cutover as the court challenge resets; FDA opens a 60-day botanical drug comment period; Missouri recalls marijuana products over chemically modified cannabinoids.
|
NEW REALM BREWING
Daily Compliance Brief
|
|
|
Vol. 1 • Edition 22 • Saturday, September 5, 2026 • Alcohol & Hemp/THC Regulation • Federal + All 50 States
|
|
|
Good morning — here's the regulatory picture for alcohol and hemp/THC beverages, readable in about three minutes. Every headline links to the original source. A quieter Friday on the alcohol side, so today's edition runs a bit shorter than usual.
|
|
Top Story
|
New Mexico retailers report six-figure losses after tracking-system cutover; court challenge withdrawn to be refiled with damages
NEW MEXICO • KUNM • Sep 4
New Mexico's switch from BioTrack to the state-built NMS2S seed-to-sale system took effect this week, and operators report immediate problems: one retailer said $460,000 of inventory was miscategorized, another said roughly 50,000 items failed to transfer, and businesses described hiring staff solely to correct errors and calculating taxes manually. Cannabis Association of New Mexico executive director Matt Kennicott said "there's a lot of things either missing or unrealistic" for operations, and High Desert Relief COO Sabrina Aragon rated the system's functionality at "probably a 4-out-of-10." The association temporarily withdrew its emergency challenge before Judge Joshua Allison and said it plans to refile next week with documented financial damages.
Why it matters: Anyone selling into New Mexico's regulated channel should reconcile inventory records against NMS2S now and document cutover-related losses — manual tax workarounds carry reporting risk, and the refiled case may turn on quantified damages.
|
|
|
Federal
FDA opens 60-day comment period on botanical drug product development
FEDERAL • FDA / Federal Register • Sep 4
FDA published a request for information in Friday's Federal Register seeking input on barriers to developing botanical drug products — plant-, algae- and fungi-derived medicines — including quality standards and study design for complex plant mixtures. Acting Commissioner Kyle Diamantas said the goal is to ensure "promising, natural health options are evaluated through rigorous science." Comments are due November 3 (Docket FDA-2026-N-9550).
Why it matters: The docket is an open channel on how FDA handles plant-derived actives — useful context, and a comment opportunity, while federal hemp product rules are being rewritten ahead of the December 11 effective date.
|
|
Around the States
Missouri regulators recall marijuana products over chemically modified cannabinoids
MISSOURI • Marijuana Moment • Sep 4
Missouri's Division of Cannabis Regulation announced a recall of marijuana products found to contain chemically modified or synthetically derived cannabinoids, continuing the state's enforcement focus on conversion-derived THC in the regulated supply chain.
Idaho voters to decide measure giving Legislature sole power to legalize marijuana
IDAHO • Marijuana Moment • Sep 3
A constitutional amendment on Idaho's November ballot would give the Legislature exclusive authority to legalize marijuana, narcotics or other psychoactive substances, ending the citizen-initiative route. Sen. C. Scott Grow (R) urged approval, citing addiction concerns, while the Natural Medical Alliance of Idaho is separately challenging the state's rejection of its competing medical cannabis initiative.
Why it matters: The outcome determines whether any future Idaho cannabis or hemp-THC market access can come from voters or only from the Legislature — a long-horizon signal for regional distribution planning.
|
|
On the Radar
Dec. 11 — The federal ban on intoxicating hemp products takes effect, following the delay signed into law this week; regulatory and legislative activity on a replacement framework continues in the interim.
Next week — The Cannabis Association of New Mexico says it will refile its NMS2S tracking-system challenge with documented financial damages.
Nov. 3 — Comments close on FDA's botanical drug products request for information (Docket FDA-2026-N-9550); Idaho's constitutional amendment on legalization authority also goes to voters in November.
|
|
Jeremy Barnes | Chief Financial Officer, New Realm Brewing Co.
Prepared for New Realm's leadership team and valued partners. This brief is for general informational purposes only and is not legal advice; it is compiled with AI assistance from the linked sources — please confirm details at the link before acting on them.
Buttons not working? Reply to this email with the word subscribe or unsubscribe. Requests are processed automatically each morning before send.
Read online & browse the archive: compliance.newrealmbrewing.com • Listen & follow: Apple Podcasts • Spotify • Amazon Music • All apps
|
|
» jbarnes@newrealmbrewing.com
» newrealmbrewing.com
» Facebook | Instagram | Twitter | LinkedIn
|
|
Audio transcript (~2 min read)
This is the New Realm Compliance Brief, Volume 1, Edition 22, for Saturday, September 5.
Our top story: New Mexico's cannabis industry completed its switch to the state's new seed-to-sale tracking system this week, and retailers say the first days have been costly. One operator reported four hundred sixty thousand dollars of inventory miscategorized in the new system, another said roughly fifty thousand items failed to transfer, and businesses described hiring extra staff just to correct errors. The head of the Cannabis Association of New Mexico, Matt Kennicott, said parts of the system are missing or unrealistic for operations, and warned that manual tax calculations create legal risk. The association temporarily withdrew its emergency court challenge and said it plans to refile next week with documented financial damages.
At the federal level, the Food and Drug Administration opened a sixty day comment period on how it regulates botanical drug products, meaning medicines derived from plants, algae, or fungi. The agency is asking for input on research barriers, quality standards, and study design. Comments are due November third.
Around the states: Missouri's Division of Cannabis Regulation announced a recall of marijuana products containing chemically modified or synthetically derived cannabinoids. And in Idaho, voters this November will decide a constitutional amendment that would give the state legislature sole authority to legalize marijuana or other psychoactive substances, ending the citizen initiative route. Republican Senator Scott Grow urged approval, citing addiction concerns, while a competing medical cannabis campaign is challenging the state's handling of its own initiative.
On the radar: the federal hemp product ban, delayed by the funding bill signed this week, is now set to take effect December eleventh. And New Mexico's refiled tracking system challenge is expected in court next week.
Full details and source links are in today's email. This update is for general information only — it is not legal advice.